Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Ally Financial Inc (ALLY), T-Mobile US Inc. (TMUS), Honeywell International Inc. (HON): BlueCrest Capital Management Loves These Stocks

BlueCrest Capital Management, managed by Michael Platt and William Reeves, recently filed its 13F filing with the U.S. Securities and Exchange Commission. The fund revealed its equity portfolio, worth $2.9 billion, for the second quarter of 2014. From the BlueCrest Capital’s portfolio, we have picked top three holdings, which include Ally Financial Inc (NYSE:ALLY), T-Mobile US Inc. (NYSE:TMUS), and Honeywell International Inc. (NYSE:HON).

Ally Financial

The top position is represented by Ally Financial Inc (NYSE:ALLY), a new position where BlueCrest Capital Management owns 2.51 million shares, with a reported value of about $60 million. Ally Financial Inc (NYSE:ALLY), an automotive financial services company, in which Stephen Feinberg’s Cerberus Capital Management reported owning 47 million shares of Ally Financial Inc (NYSE:ALLY). In its latest 13F filing, Canyon Capital Advisors, managed by Joshua Friedman and Mitchell Julis, disclosed holding 11.36 million shares of the company. For second quarter of 2014, Ally Financial Inc (NYSE: ALLY) posted net income of $323 million, or $0.54 per diluted common share, compared to a net loss of $927 million, or a loss of $2.73 per diluted common share, for the quarter last year.

In T-Mobile US Inc. (NYSE:TMUS), BlueCrest Capital Management boosted its stake to 636,037, worth $21.4 million, from 44,700 shares the fund reported previously. For the second quarter of 2014, T-Mobile reported 1.5 million total net customer additions with more than 1.0 million total branded net customer additions, including branded postpaid net additions of 908,000 and branded prepaid net additions of 102,000, according to a press release. T-Mobile US Inc. (NYSE:TMUS) has a market cap of $23.5 billion.

Other significant shareholders of T-Mobile US Inc. (NYSE:TMUS) include Paulson & Co, led by John Paulson, which disclosed ownership of 13.16 million shares, and Glenview Capital, managed by Larry Robbins, which holds 8.45 million shares of the company.

BlueCrest Capital Management also upped its position in Honeywell International Inc. (NYSE:HON) during the second quarter. The fund holds 182,131 shares of Honeywell International Inc. (NYSE:HON), which is a Fortune 100 diversified technology and manufacturing company. Recently, Honeywell International Inc. (NYSE:HON) announced that it has decided to voluntarily withdraw the listing of its common stock from the Chicago Stock Exchange to streamline operations and eliminate duplicative administrative requirements and costs inherent with dual listings. The withdrawal is expected to be effective within the next month.

Other hedge fund having big stakes in Honeywell International Inc. (NYSE:HON) include Adage Capital Management, managed by Phill Gross and Robert Atchinson, which holds 4.11 million shares, and Ken Griffin’s Citadel Investment Group, which owns 3.02 million shares of the company.

BlueCrest Capital Management is an alternative asset management firm that was founded by Williams Reeves and Michael Platt in 2000. Both Williams Reeves and Michael Platt were managing directors and senior proprietary traders at JP Morgan before launching BlueCrest Capital Management LP.

Disclosure: none

Biotech Insider Alert - $5 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...
X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!